FDA issues not approvable letter to Cellegy Pharmaceuticals
Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).
View ArticleBotox - other applications
While botulinum toxin A, or BTXA, is widely known for its use in dermatology and aesthetic medicine, a review article in the Journal of Cosmetic Dermatology explores the drug’s other successful...
View ArticleFDA approves ProStrakan's Rectiv for pain associated with anal fissures
ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that it has received approval from the U.S. Food and Drug...
View ArticleStudy supports sphincter-saving surgery
Fissurectomy results in high levels of healing and low rates of anal incontinence, show the results of the largest ever prospective study of the technique.
View ArticleExclusion diet boosts anal fissure healing
Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have...
View ArticleApremilast drug shows promise for Behcet's ulcers
Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment...
View Article
